Investigational — This vaccine is not yet approved for general use. Information is for educational purposes only. Participation in clinical trials requires enrolment at an authorised trial centre.
Russian mRNA Cancer Vaccine
Also known as: Gamaleya personalised mRNA vaccine · NMIC mRNA cancer vaccine · Russia free cancer vaccine 2024
In late 2023 and early 2024, Russia's Health Minister Mikhail Murashko and President Vladimir Putin publicly announced that Russia had developed a personalised mRNA cancer vaccine and that it would be made available free of charge to Russian citizens through clinical trials. The vaccine is being developed jointly by the Gamaleya Research Centre (known for Sputnik V COVID vaccine) and the Blokhin Cancer Research Centre, Russia's leading oncology institute. Like the Moderna/Merck and BioNTech approaches, it encodes patient-specific neoantigens derived from tumour sequencing. Independent peer-reviewed efficacy data is not yet publicly available — the announcement predates published clinical trial results. International oncologists are cautiously watching for data.
What It Targets
Target Antigen
Patient-specific tumour neoantigens (individualised per patient)
Cancers Targeted
How It Works
As with other personalised mRNA cancer vaccine platforms: patient tumour DNA is sequenced → mutations are identified → neoantigen-encoding mRNA sequences are synthesised → formulated in lipid nanoparticles → injected to prime tumour-specific T-cell responses. The specific adjuvant system, manufacturing process, neoantigen selection algorithm, and clinical protocol details have not been published in peer-reviewed literature as of early 2024.
Key Trial Results
- Russian government announced Phase 1 trials initiated in 2023 across multiple cancer types
- Health Minister Murashko (Jan 2024): vaccine will be registered and available free to Russian patients 'very soon'
- Gamaleya centre reports early Phase 1 safety data is satisfactory — no published peer-reviewed immunogenicity or efficacy data yet
- Registration of the vaccine anticipated for 2025 pending Phase 2 results under Russia's accelerated pathway
- Independent verification: international oncology community notes the announcement is politically timed; peer-reviewed data publication is the critical next step
Regulatory Status & Availability
Approval Status
Phase 1 clinical trials ongoing in Russia (2023–2024). Russian health ministry announced free access for registered trial participants.
Estimated Availability
Phase 1 trials now — broader availability 2027+ if efficacy proven
Important Considerations
- No peer-reviewed efficacy or immunogenicity data published as of early 2024 — announcement predates evidence
- Political context: announcement came during geopolitical tensions — independent replication and data transparency essential
- Not accessible outside Russia under current circumstances
- Manufacturing quality standards and regulatory pathway differ from FDA/EMA frameworks
- Patients outside Russia should follow EU/US trials (Moderna-Merck, BioNTech) which have published Phase 2/3 data
Research References
iOnco provides this information for educational purposes only. Cancer vaccine availability, trial eligibility, and access pathways change frequently. Always discuss vaccination decisions and clinical trial participation with your oncologist or healthcare provider.